Labcorp Acquires BioReference Health’s Oncology Testing Division for $192 Million

Labcorp has announced the acquisition of BioReference Health’s cancer testing business in a deal valued at $192 million. The transaction involves the oncology-focused division of BioReference Health, which is owned by Opko Health. This move comes as Opko Health continues efforts to streamline operations and reduce expenses in pursuit of profitability.

BioReference Health, known for its diagnostic services, has been undergoing cost-cutting measures under its parent company, Opko Health. The sale of its oncology testing segment marks a strategic shift for the company as it seeks financial stability. Labcorp, a global leader in laboratory diagnostics and testing services, will integrate this new acquisition into its portfolio to expand its capabilities in cancer diagnostics.

Date: March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

GSK Successfully Acquires Clinical-Stage Company IDRx, Inc. to Enhance Cancer Treatment Options AstraZeneca Acquires Cell Therapy Company in $1 Billion Deal to Develop In Vivo Cancer Treatments ZYN Nicotine Pouches Receive FDA Marketing Authorization Measles Outbreak in the United States: A Resurgence of a Vaccine-Preventable Disease

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後